Strengthening the R&D organization by incorporating the world's most advanced expertise and technologies
First written in FY2016. 17 of 23 entries say "Advanced", first in FY2019. Latest entry: FY2026.
25 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「There are currently 28 new drug candidates in the clinical development stage in the priority areas, of which 19 were discovered internally. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research.」
The number of candidates in the clinical development stage in the priority areas increased from 24 to 28, while the number of internally discovered candidates increased from 15 to 19. The strengthening of translational research is continuing. - FY2026-H1AdvancedAnnual report
「In drug discovery research, we have designated oncology, immunology, neurology and specialty areas, where medical needs are high, as priority areas. We aim to deepen our understanding of human disease biology in each area and create new drugs capable of meeting medical needs. By actively promoting open innovation, an area in which we have particular expertise, we identify original drug discovery seeds and strengthen our drug discovery capabilities by using the optimal modalities and advanced technologies such as digital technology. There are currently 24 new drug candidates in the clinical development stage in the priority areas, of which 15 were discovered internally. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research.」
There are 24 candidates in the clinical development stage in the priority areas, of which 15 were discovered internally, demonstrating an R&D organization combining open innovation, optimal modalities, digital technologies and translational research. - FY2025AdvancedAnnual report
「There are currently 14 new drug candidates in the priority areas that have entered the clinical stage, of which 3 are from Deciphera. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research.」
The number of candidates in the clinical stage remained at 14, but the number from Deciphera increased from 2 to 3, and the strengthening of translational research was reaffirmed. - FY2025-H1AdvancedAnnual report
「There are currently 14 new drug candidates in the clinical stage in the priority areas, of which 2 are from Deciphera. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research.」
The number of candidates in the clinical stage in the priority areas increased from 11 to 14, including 2 from Deciphera. The continued strengthening of translational research is also stated. - FY2024AdvancedAnnual report
「There are currently 11 new drug candidate compounds in the clinical stage in the priority areas. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research. By organically using research tools such as human genomic information and human iPS cells together with informatics from the early stages of research, we are working to analyze the relationship between target molecules and diseases and identify physiological indicators (biomarkers) that can more accurately predict and evaluate the efficacy of new drug candidate compounds in humans.」
The number of internally discovered candidates in the clinical stage increased from 10 to 11, and the continued strengthening of R&D using human genomics, iPS cells and informatics, as well as translational research, is described. - FY2024-Q3AdvancedAnnual report
「As of 24 January 2024 ※2: We started a Phase I study in Japan of the subcutaneous formulation ONO-4538HSC (a combination product of nivolumab and berahyaluronidase alfa) of ONO-4538 in patients with “solid tumors.” ※3: We started a Phase I study in the United States of the iPS cell-derived HER2 CAR-T cell therapy “ONO-8250” in patients with “HER2-positive solid tumors.”」
Phase I studies were initiated in Japan for ONO-4538HSC and in the United States for the iPS cell-derived HER2 CAR-T cell therapy ONO-8250, advancing the R&D pipeline into new clinical stages. - FY2024-Q2AdvancedAnnual report
「There are currently 9 internally discovered new drug candidate compounds in the clinical stage in the priority areas. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research. By organically using research tools such as human genomic information and human iPS cells together with informatics from the early stages of research, we are working to analyze the relationship between target molecules and diseases and identify physiological indicators (biomarkers) that can more accurately predict and evaluate the efficacy of new drug candidate compounds in humans.」
9 internally discovered candidates in the priority areas are in the clinical stage, and specific efforts to strengthen R&D using human genomics, iPS cells and informatics, as well as translational research, are described. - FY2024-Q1AdvancedAnnual report
「Changes from the financial results announcement for the fiscal year ended March 2023 ※3: We started a Phase I study in Japan of the combination therapy of the anti-ILT4 antibody “ONO-7226” and “Opdivo” in patients with “solid tumors.”」
A Phase I study in Japan was initiated for combination therapy with the anti-ILT4 antibody ONO-7226 and Opdivo, advancing the R&D pipeline into a new clinical trial stage. - FY2023AdvancedAnnual report
「There are currently 10 internally discovered new drug candidate compounds in the clinical stage in the priority areas, and we are also strengthening translational research bridging basic and clinical research to further improve the speed and probability of success in drug discovery.」
The number of internally discovered candidates in the clinical stage in the priority areas increased from 8 to 10, and the strengthening of translational research is also explicitly stated. - FY2023-Q2AdvancedAnnual report
「In August this year, we started a Phase I study in the United States of the MALT1 inhibitor “ONO-7018” in patients with “non-Hodgkin lymphoma and chronic lymphocytic leukemia.”」
For ONO-7018, a Phase I study targeting non-Hodgkin lymphoma and chronic lymphocytic leukemia was initiated in the United States, advancing the R&D pipeline into the clinical stage. - FY2023-Q1AdvancedAnnual report
「※2: We started a Phase I study in the United States of the epigenetic regulator “ONO-2020” in patients with “neurodegenerative diseases.”」
For the epigenetic regulator ONO-2020, a Phase I study targeting neurodegenerative diseases was initiated in the United States, marking the R&D pipeline’s entry into the clinical stage. - FY2022AdvancedAnnual report
「8 new drug candidate compounds in the priority areas have entered the clinical stage, and we are also strengthening translational research bridging basic and clinical research to further improve the speed and probability of success in drug discovery.」
The number of candidate compounds in the priority areas that have entered the clinical stage increased from the previously reported 7 to 8, and the strengthening of translational research is continuing. - FY2022-Q3AdvancedAnnual report
「※5: We started a Phase III study in Japan of the anti-CD47 antibody “ONO-7913” in patients with “TP53 mutation-positive acute myeloid leukemia.” / ※6: We started Phase III studies in South Korea and Taiwan of the anti-CD47 antibody “ONO-7913” in patients with “acute myeloid leukemia.”」
For the anti-CD47 antibody ONO-7913, Phase III studies targeting acute myeloid leukemia were initiated in Japan, South Korea and Taiwan, advancing the R&D pipeline into the late clinical stage. - FY2022-Q2AdvancedAnnual report
「In drug discovery research, we have designated oncology, immunology, neurology and specialty areas, where medical needs are high, as priority areas. To strengthen our drug discovery capabilities in each area, we will deepen our understanding of human disease biology and promote efforts to appropriately identify medical needs. We will also promote open innovation to acquire original drug discovery seeds and use the latest technologies, including informatics, human disease model development and compound synthesis, to create groundbreaking new drugs with a significant medical impact. 7 new drug candidate compounds in the priority areas have entered the clinical stage, and we will also strengthen translational research bridging basic and clinical research to further improve the speed and probability of success in drug discovery.」
The policy of strengthening R&D through priority areas, open innovation and technologies such as informatics and human disease models is described, along with the entry of 7 candidate compounds into the clinical stage and the strengthening of translational research. - FY2020RestatedAnnual report
「Based on our proprietary drug discovery approach, “Compound-Oriented,” we have designated oncology, immunology, central nervous system diseases and specialty areas, where medical needs are high, as priority research areas. We will accumulate disease expertise in each area and create new drugs that bring innovation to clinical practice.」
The policy of transforming the R&D organization based on priority research areas, the accumulation of disease expertise and the Compound-Oriented approach is reaffirmed. - FY2019AdvancedAnnual report
「Based on our conventional compound-oriented approach, we established the Oncology Research Center, Immunology Research Center, Neurology Research Center and Specialty Research Center for the respective priority areas, with the aim of accumulating disease expertise and appropriately identifying medical needs.」
The establishment of 4 research centers for the respective priority areas is described as a concrete milestone in the transformation of the R&D organization. - FY2018ReframedAnnual report
「Going forward, while building on this approach, we will designate oncology, immunology and central nervous system diseases, where medical needs are high, as priority research areas and concentrate our management resources on them. In addition to strengthening drug discovery based on conventional small molecules and antibodies, we will also take on drug discovery using new modalities such as cell therapies and mid-sized molecules. Furthermore, by promoting an open innovation strategy and incorporating world-leading knowledge and technologies through joint research with biotechnology ventures, universities and research institutions in Japan and overseas, we will accelerate the creation of new drugs that bring innovation to clinical practice.」
The previous policy of strengthening the R&D organization has been developed into a specific transformation of R&D focused on oncology, immunology and central nervous system diseases and incorporating new drug discovery modalities and open innovation. - FY2018-Q2RestatedAnnual report
「Going forward, in addition to aiming to create original and groundbreaking pharmaceuticals using world-leading technologies in Japan and overseas, we will work to introduce promising compounds through licensing activities and further strengthen our R&D activities.」
The policy of strengthening R&D by using advanced technologies in Japan and overseas and introducing compounds through licensing is reaffirmed. - FY2017RestatedAnnual report
「We are strengthening our R&D organization by incorporating world-leading knowledge and technologies into our own expertise so that we can create innovative new drugs.」
The policy of strengthening the R&D organization by combining the company’s own expertise with world-leading knowledge and technologies is reaffirmed. - FY2017-Q2RestatedAnnual report
「Going forward, in addition to aiming to create original and groundbreaking pharmaceuticals using world-leading technologies in Japan and overseas, we will work to introduce promising compounds through licensing activities and further strengthen our R&D activities.」
The policy of strengthening R&D activities by using advanced technologies in Japan and overseas is reiterated. - FY2016First statedAnnual report
「We are strengthening our R&D organization by incorporating world-leading knowledge and technologies into our own expertise so that we can create innovative new drugs.」
This describes the approach of strengthening the R&D organization by combining the company’s own expertise with advanced external knowledge and technologies.